-
A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma
Sep 9, 2025, 16:22 PM -
Supplementing Single-Arm Trial Data in NICE Submissions: Are Synthetic Approaches Leading the Charge?
Sep 9, 2025, 16:22 PM -
The Impact of the Introduction of Diagnosis-Related Groups (DRG)-Based Hospital Financing on the Performance of Romanian Hospitals
Sep 9, 2025, 16:22 PM -
Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients With Early Breast Cancer
Sep 9, 2025, 16:22 PM -
How Far Have We Come With EQ-5D-5L Value Sets? An Updated Systematic Literature Review of 55 Valuation Studies
Sep 9, 2025, 16:22 PM -
Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing
Sep 9, 2025, 16:22 PM -
International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece
Sep 9, 2025, 16:22 PM -
Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer
Sep 9, 2025, 16:22 PM -
Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025
Sep 9, 2025, 16:22 PM -
Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Economic Evaluation of Synovial Biopsy-Guided Treatment Strategy After TNF-Alpha Inhibitor Failure in Rheumatoid Arthritis
Sep 9, 2025, 16:22 PM -
Does the Joint Clinical Assessment (JCA) Enable Health Equity Across Europe? A Review of HTA Practices in the EU
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Morocco
Sep 9, 2025, 16:22 PM -
Beyond the Guidelines: Exploring the Characteristics and Comorbidity Profiles of Adults With Pneumococcal Disease in England Not Covered by Current Pneumococcal Vaccination Criteria
Sep 9, 2025, 16:22 PM
